Short Interest in Genmab A/S (NASDAQ:GMAB) Drops By 6.4%

Genmab A/S (NASDAQ:GMAB) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,620,000 shares, a drop of 6.4% from the January 15th total of 1,730,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.3% of the company’s shares are sold short.

Genmab A/S Stock Performance

GMAB traded up $0.30 during trading on Tuesday, hitting $21.60. The stock had a trading volume of 1,095,717 shares, compared to its average volume of 1,563,852. The company has a market capitalization of $14.29 billion, a PE ratio of 20.97, a PEG ratio of 0.54 and a beta of 0.96. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88. The stock has a 50 day simple moving average of $20.64 and a two-hundred day simple moving average of $23.02.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. On average, equities research analysts anticipate that Genmab A/S will post 1.25 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GMAB. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Deep Track Capital LP purchased a new position in shares of Genmab A/S during the fourth quarter worth $41,740,000. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S during the fourth quarter worth $33,804,000. Two Sigma Advisers LP raised its holdings in shares of Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after purchasing an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock worth $23,422,000 after purchasing an additional 694,243 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.